Clinical trials referenced in this document:
Documents that mention this clinical trial
RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer
Received: 8 September 2020
Accepted: 23 November 2020
First Online: 1 December 2020
Change Date: 12 October 2021
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1186/s13550-021-00851-1
Ethics approval and consent to participate
: Institutional ethics approval for this study was obtained from Shanghai General Hospital Ethics Committee (2016KY220). Participants enrolled in the study provided written informed consent to participate.
: Not applicable.
: DJH has received honoraria from Novartis and research funding from NanoMab Technology Limited. GC provides consultancy for NanoMab Technology Limited. VG has received research support from Siemens Healthcare. GJRC has received research support from NanoMab Technology Ltd., Theragnostics Ltd. and Serac Healthcare Ltd. and provides consultancy for GE Healthcare and NanoMab Technology Ltd.